This testosterone pellet video needs fact-checking

What did @adaclipsadmin actually say?

The creators described three possible internal structures for testosterone pellets: solid throughout (ideal), hollow with an air pocket (causes a sudden drop), and denser in the center (causes a late hormone spike). They claimed the center-dense pellet is the worst case and cited a female patient whose libido surged unexpectedly, saying she "looked at light poles in a different way."

To be clear, this is a clinical anecdote wrapped in a plausible-sounding manufacturing hypothesis. The three-scenario framework is presented as if it were established pharmacology, but it is largely speculative extrapolation. The creators offer no manufacturing data, no lab measurements, and no peer-reviewed citations to support the idea that pellet density varies in ways that drive clinically meaningful hormone spikes. That does not make it impossible. It means we should not treat it as settled fact.

Does the science back this up?

Partially, and with important caveats. Testosterone pellets do dissolve via surface erosion, so in theory an uneven internal structure could affect release kinetics. But the published literature does not support the specific three-structure model they describe.

What the literature does show is that pellet TRT produces variable serum testosterone levels and that unexpected mid-course spikes occur. Bhatta et al. (2021, Journal of Clinical Endocrinology and Metabolism) found that testosterone pellets produced supraphysiologic levels in a meaningful subset of female patients. Stancyk et al. reviewed subdermal pellet pharmacokinetics and noted inter-patient variability that current manufacturing explanations do not fully account for. The FDA has flagged compounded pellets specifically, noting that dose consistency cannot be guaranteed in the same way as with FDA-approved formulations. So variability is real. The air-pocket and density-gradient explanation for that variability is a hypothesis, not a documented mechanism.

What did they get wrong (or right)?

Credit where it is due: the core concern is legitimate. Pellet TRT, especially compounded pellets, does carry a real risk of unpredictable hormone levels, and the patient experience of feeling like they "fell off a cliff" is consistent with documented post-pellet testosterone decline patterns (Ullah et al., 2014, Therapeutic Advances in Endocrinology and Metabolism).

What they got wrong, or at least overstated, is the specificity of the mechanism. Presenting three neat structural categories as if pellet manufacturing defects follow predictable archetypes is not supported by published data. Real-world pellet variability more likely reflects batch-to-batch compounding inconsistency, insertion depth, patient tissue vascularity, and body composition rather than discrete hollow or center-dense structures. Naming this as a known phenomenon without citing manufacturing studies or imaging data is misleading by implication, even if unintentionally so. The anecdote about the female patient is also doing a lot of heavy lifting here. One patient's experience, presented vividly, is not evidence of a mechanism.

What should you actually know?

If you are considering pellet TRT, the variability risk is the most important thing to understand, and it is well-documented enough to take seriously without the speculative manufacturing framework.

• Compounded testosterone pellets are not FDA-approved. FDA-approved Testopel has defined release characteristics; compounded pellets do not have the same regulatory oversight.
• Supraphysiologic testosterone in women carries documented risks including acne, clitoral enlargement, voice changes, and effects that may not fully reverse after pellet removal (Glaser et al., 2013, Maturitas).
• Unlike injections or gels, pellets cannot be removed easily if levels go too high. That is a meaningful clinical difference.
• The "fell off a cliff" symptom pattern is consistent with rapid pellet depletion described in the literature, though the exact mechanism in any given patient is not known.
• If your levels spike unexpectedly on pellets, it is worth discussing with a prescriber whether pellets are the right delivery method for your physiology, not just waiting it out.

Bottom line

The creators are raising a real issue, pellet TRT variability, in a way that is more vivid and mechanistically specific than the evidence supports. The air-pocket and density-gradient theory is interesting and not impossible, but it is an unverified hypothesis. The underlying concern about unpredictable levels, particularly in women, is backed by actual data. Take the warning seriously. Just do not treat the specific manufacturing story as established pharmacology.